Phase Separation of AKAP95 Regulates Oncogenic MLL-fusion Driven Transcription and Its Modulation for Cancer Therapy

Wei Li
DOI: https://doi.org/10.21203/rs.3.rs-5274238/v1
2024-01-01
Abstract:RNA binding proteins (RBPs) have been reported to own genome-wide chromatin binding sites, and are supposed to regulate transcription directly. However, the molecular detail about RBPs regulating transcription is still unclear. Here, we showed the RBP AKAP95 engaged in transcription regulation through tethering itself to nascent RNA on chromatin. Further, phase separation enabled AKAP95 having large spectrum coverage on transcription start sites and meanwhile recruiting RNA polymerase II CTD to activate transcription. This transcription co-activation mechanism was hijacked in MLL rearranged (MLLr) leukemia. AKAP95 was enclosed in the same condensates with MLL1 translocated fragment. It was required for MLLr leukemogenesis, but not for normal and regenerative hematopoiesis, rendering AKAP95 an ideal target for leukemia therapeutics. As an endeavor for modifying condensates, we designed a peptide bridging AKAP95 with protein quality surveillance component HSP70. This peptide successfully impaired AKAP95 phase separation, transcription activation and cancer cell growth, attesting the concept that oncogenic condensates is druggable.
What problem does this paper attempt to address?